Global Mild Traumatic Brain Injury treatment Market, by Treatment Type (Pain relievers, Diuretics, Anti-seizure drugs, Coma-inducing drugs), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2019 and 2027.
As per the report, increasing incidence of brain injuries due to accidents and prevalence of neurodegenerative diseases are attributed to growth in mild traumatic brain injury treatment market. As per Department of Neurology, University of California San Francisco, each year 42 million people across the globe suffer from mild traumatic brain injury (MTBI). As per CDC, incidence of post traumatic brain injury exceeds 600 per 100,000 people across the globe. Some of the established risk factors for mild traumatic brain injury are Alzheimer's disease, Parkinson's disease, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis (ALS). According to Alzheimer’s Association, Alzheimer’s disease is a 6th leading cause of death in the U.S> and approximately 5.8 million Americans are suffering from Alzheimer’s disease. In 2019, Alzheimer’s and other dementia are estimated to cost the Nation around US$ 290 billion. Mild traumatic brain injury is acute brain injury resulting from mechanical energy to the head from external physical forces. MTBI is extremely common. It is estimated that 100 to 300 per 100,000 people seek medical attention for MTBI annually worldwide. Improving treatment seeking rate would thus push the market growth for mild traumatic brain injury treatment.